The recombinant chimeric plasminogen activator, rt-PA-AFE/ scu-PA-e, consisting of amino acids 1 t o 3 and 87 t o 274 of tissue-type plasminogen activator (t-PA) and amino acids 138 t o 41 1 of single-chain urokinase-type plasminogen activator (scu-PA), has a markedly increased thrombolytic potency following its continuous intravenous infusion in animal models of venous thrombosis (Collen et al, Circulation, in press). In the present study, the thrombolytic potencies of intravenous bolus injections of rt-PA-AFE/scu-PA-e, of recombinant t-PA (rt-PA), and of recombinant scu-PA (rscu-PA), given alone or in combination, were compared with those of intravenous infusions in a hamster pulmonary embolism model. Dose-dependent clot lysis was obtained in the absence of systemic activation of the fibrinolytic system and fibrinogen breakdown. In bolus injection experiments, the maximal rate of clot lysis, expressed in percent clot lysis per milligrams per kilogram compound administered, was 120 f 10 for rt-PA, 54 f 8 for rscu-PA, and 2,100 * 500 for HE THROMBOLYTIC AGENTS recombinant hu-
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The recombinant chimeric plasminogen activator, rt-PA-AFE/ scu-PA-e, consisting of amino acids 1 t o 3 and 87 t o 274 of tissue-type plasminogen activator (t-PA) and amino acids 138 t o 41 1 of single-chain urokinase-type plasminogen activator (scu-PA), has a markedly increased thrombolytic potency following its continuous intravenous infusion in animal models of venous thrombosis (Collen et al, Circulation, in press). In the present study, the thrombolytic potencies of intravenous bolus injections of rt-PA-AFE/scu-PA-e, of recombinant t-PA (rt-PA), and of recombinant scu-PA (rscu-PA), given alone or in combination, were compared with those of intravenous infusions in a hamster pulmonary embolism model. Dose-dependent clot lysis was obtained in the absence of systemic activation of the fibrinolytic system and fibrinogen breakdown. In bolus injection experiments, the maximal rate of clot lysis, expressed in percent clot lysis per milligrams per kilogram compound administered, was 120 f 10 for rt-PA, 54 f 8 for rscu-PA, and 2,100 * 500 for HE THROMBOLYTIC AGENTS recombinant hu-T man tissue-type plasminogen activator (rt-PA) and recombinant human single-chain urokinase-type PA (rscu-PA) both have a very short plasma half-life in man as a result of rapid hepatic clearance.'.2 Their therapeutic use in patients with acute myocardial infarction, therefore, probably requires continuous intravenous infusion of relatively large amounts of material (50 to 100 mg), which may be associated with some systemic fibrinolytic activation? Therefore, the quest for improved thrombolytic agents or administration schemes remains open. In an effort to achieve higher patency rates with fewer side effects, the use of a combination of two PAS in reduced doses has been studied. A synergistic effect of rt-PA and rscu-PA was demonstrated in a rabbit jugular vein thrombosis model: in a coronary artery thrombosis model in the dog: and in initial studies in patients with acute myocardial infarcti~n.~.' However, synergism between t-PA and scu-PA was not confirmed in subsequent studies. 8 In another approach, preliminary experiments with bolus administration of rt-PA in patients with acute myocardial infarction'.'' have yielded similar patency rates as the infusion regimen.
In an effort to combine the mechanisms of the fibrinspecificity of t-PA and scu-PA, recombinant chimeric molecules have previously been constructed consisting of the A-chain of t-PA (containing the fibrin-binding domains) and the protease domain of SCU-PA.".'~ Such chimeric molecules had intact enzymatic properties of scu-PA, but had only partially acquired the fibrin-affinity of t-PA. To investigate the structural basis of this impaired fibrinaffinity, a set of domain deletion and/or duplication mutants of such chimera was constr~cted.'~ Surprisingly, one of these chimeric PAS (rt-PA-AFE/scu-PA-e) with little or no fibrin-affinity," was found to have a markedly enhanced thrombolytic potency following continuous intravenous infusion in animal models of thr0mbo~is.l~ This increased potency appeared to be due to an approximately 10-fold rt-PA-AFE/scu-PA-e (P < .01 Y rt-PA or rscu-PA). Comparative results with continuous infusion over 1 hour were 270 & 64, 99 2 18, and 1,500 f 250 (P < .01 v rt-PA or rscu-PA) percent lysis per mg/kg compound infused for rt-PA, rscu-PA, and rt-PA-AFElscu-PA-e, respectively. Thus, rt-PA and rscu-PA are more potent when administered as an infusion than as a bolus, whereas rt-PA-AFE/scu-PA-e is at least as potent when administered as a bolus. Combined bolus injections of rt-PA and rscu-PA had a 2.2-fold synergistic effect on clot lysis, but no synergism was observed with combined bolus injections or with combined infusions of rt-PA and rt-PA-AFEI scu-PA-e, or of rscu-PA and rt-PA-AFEfscu-PA-e. The present study thus shows that rt-PA-AFE/scu-PA-e is much more potent for clot lysis than rt-PA or rscu-PA when administered as a bolus injection, but no synergistic interaction is observed between the chimera and either rt-PA or rscu-PA. 0 1991 b y The American Society of Hematology.
reduced clearance with maintained specific thrombolytic a~tivity.'~ In the present study, we have evaluated thrombolysis with single and combined intravenous infusion or bolus injection of rt-PA-AFEiscu-PA-e, rt-PA, and rscu-PA in a hamster pulmonary embolism model. 
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LU ETAL the test drug. Thrombolytic agents or saline were administered either as a continuous intravenous infusion over 60 minutes or as a bolus injection over 1 minute. Thirty minutes after the end of the infusion or 90 minutes after the bolus injection, the extent of clot lysis was determined as the difference between the radioactivity initially incorporated in the clot and the residual radioactivity in the lungs and the heart. An isotope recovery balance was made by adding the radioisotope content recovered in the heart and lungs and that in the blood (multiplied with a factor 3 to correct for extravascular distribution) at the end of the experiment. Blood samples (0.2 mL) were drawn into trisodium citrate (0.11 molL final concentration) just before the start of the infusion or the injection of the bolus, and 60 and 90 minutes later. Blood samples were centrifuged and the plasma was frozen immediately. These blood samples were used for measurement of fibrinogen and cyantiplasmin and in some experiments for t-PA-related or u-PA-related antigen determination. Fibrinogen was determined with a clotting rate assayI6 and q-antiplasmin with a chromogenic substrate assay." t-PA-related and u-PA-related antigen were measured with specific enzyme-linked immunosorbent assays (ELISAs).l8.l9 rt-PA-AFEiscu-PA-e was determined using a four compartment (each 100 pL) radioimmunoassay,*' consisting of dilutions of test sample or standard, '251-labeled rt-PA-AFElscu-PA-e (20,000 cpm), rabbit antiserum raised against t-PA (for rt-PA-AFE/scu-PA-e and its combinations with rscu-PA) or rabbit antiserum raised against u-PA (for combinations of rt-PA-AFEiscu-PA-e and rt-PA), and Sac-Cel (donkey antirabbit IgG, Wellcome Diagnostics, IDS, Washington). After 30 minutes of incubation, the radioisotope associated with the gel was determined.
Results are expressed as mean f SEM, and significance of the differences between groups evaluated using Student's t-test. The thrombolytic potency of the agents, administered as an infusion or as a bolus injection, was determined in the following way. The mean values of the percent lysis (y) versus dose in milligrams per kilogram (x) were fitted with an exponentially transformed sigmoidal function y = 1OOc/l + e-a(ez--cbl, using the statistical program Grafit (Erithacus Ltd, Middlesex, UK). The mean 2 SEM of the parameters c (maximal lysis in percent), b (dose in milligrams per kilogram at which the rate of clot lysis is maximal), and z = acl4 . eb (maximal rate of lysis, expressed as percent lysis per milligrams per kilogram compound administered) were determined.
The synergistic effect of combinations of rt-PA and rscu-PA, of rt-PA and rt-PA-AFEIscu-PA-e, or of rscu-PA and rt-PA-AFElscu-PA-e on thrombolysis was determined as follows.z1 The slope of the dose-response curves of each agent alone (expressed in percent clot lysis per milligrams per kilogram compound administered) was determined by linear regression analysis, both for bolus injection and continuous infusion. Equipotent fractional doses of the individual agents were determined by multiplying the administered doses (in milligrams per kilogram) with the slope of the dose-response curve (expressed as a fraction of 100 percent lysis per milligrams per kilogram compound). For instance, rt-PA produced a doseresponse curve with a slope of 77% lysis per milligrams per kilogram administered as a bolus, whereas rscu-PA yielded a corresponding value of 36% lysis per milligrams per kilogram compound administered. Thus, the equipotent doses were obtained by multiplying the administered doses with 0.77 and 0.36 for rt-PA and rscu-PA, respectively. This linear transformation resulted in superimposable dose-response curves for the individual agents. The doses of the agents used in the combinations were then expressed as the sum of the fractional equipotent doses of each agent, and the percent clot lysis obtained with the combinations was plotted against the total fractional dose. The slopes of the normalized curves obtained with the combinations were then
Data analysis.
compared with those of the agents administered alone (which are normalized to 100% lysis per unit fractional dose).
RESULTS
The thrombolytic properties of rt-PA, rscu-PA, and rt-PA-AFE/scu-PA-e, following intravenous infusion over 60 minutes or bolus injection over 1 minute in hamsters with pulmonary embolism, are summarized in Tables 1 and  2 . All PAS induced dose-dependent clot lysis, both when administered as an infusion or as a bolus. Significant systemic activation of the fibrinolytic system was not observed, as shown by a lack of g-antiplasmin consumption and fibrinogen breakdown at the end of the experiments. The dose-response data were fitted with the exponentially transformed sigmoidal function, with results illustrated in Fig 1. In agreement with earlier finding^,'^ the thrombolytic potency of intravenously infused rt-PA-AFE/scu-PA-e is significantly higher than that of rt-PA or rscu-PA. This marked difference between the chimera and the parent molecules is also observed following bolus injection ( Table  2 ). The higher thrombolytic potency of the chimera is shown by both a significantly lower b value (which represents the dose administered, expressed in milligrams per kilogram, at which the rate of clot lysis is maximal) and a higher z value (which is the maximal rate of clot lysis, expressed as percent lysis per milligrams per kilogram compound infused) ( Table 3 ). The b values were 0.028 f 0.003 m a g for rt-PA-AFE/scu-PA-e, 0.058 f 0.015 mgkg for rt-PA (P = .18 v the chimera), and 0.34 2 0.042 mgkg for rscu-PA (P < .001 v the chimera), when administered in infusions, and 0.015 f 0.003 mgkg for rt-PA-AFE/scu-PA-e, 0.20 f 0.018 mgkg for rt-PA (P < .001), and 0.50 f 0.065 mgkg for rscu-PA (P < .001), for bolus injections.
The corresponding z values, expressed in percent lysis per milligrams per kilogram compound administered, were 1,500 f 250 for rt-PA-AFElscu-PA-e, 270 f 64 for rt-PA (P < .001), and 99 f 18 for rscu-PA (P < .001), when administered as infusions, and 2,100 f 500 for rt-PA-AFE/ scu-PA-e, 120 f 10 for rt-PA (P = .002), and 54 f 8 for rscu-PA (P = .003), when administered as a bolus.
Comparison of the results obtained with infusions with those obtained with bolus injections showed a higher thrombolytic potency of rt-PA when administered as an infusion (characterized by a higher z value of 270% lysis per mgkg compound administered and a lower b value of 0.058 mgkg as compared with values of 120% lysis per mgkg and 0.20 mg/kg, respectively for bolus injection; P = .054 and P < .001, respectively). The thrombolytic potency of rscu-PA, when administered as an infusion was also higher than that obtained with bolus injection (characterized by a z value of 99% lysis per m a g and a b value of 0.34 mgkg as compared with values of 54 and 0.50 obtained with bolus injection; P = .052 and P = .073, respectively). In contrast, the thrombolytic potency of rt-PA-AFE/scu-PA-e appeared to be at least as high when administered as a bolus injection as when administered as an infusion (characterized by a z value of 2,100 and a b value of 0.015 for bolus administration as compared with the values of 1,500 and 0.028 for infusions; P = .36 and P = .71, respectively).
For The thrombolytic properties of combinations of rt-PA and rt-PA-AFE/scu-PA-e, of rscu-PA and rt-PA-AFElscu-PA-e, or of rt-PA and rscu-PA following intravenous infusion over 60 minutes or bolus injection over 1 minute in hamsters with pulmonary embolism are also summarized in Tables 1 and 2 . These combinations induced very similar dose-dependent lysis without extensive systemic fibrinolytic activation, both when administered as an infusion or as a bolus injection. For the evaluation of synergistic interactions, the dose-response data were fitted with a straight line by linear regression analysis. The thrombolytic potency was determined as the slope of the regression line of the dose-response data, and expressed in percent lysis per milligrams per kilogram compound administered. The thrombolytic potency of rt-PA-AFE/scu-PA-e determined in this way was much higher than that of rt-PA or of rscu-PA, both when administered as an infusion (1,100% f 220% lysis per mgikg, as compared with 160% f 34% for rt-PG P < .003, and 43% ? 14% for rscu-PA, P < .006) or when administered as a bolus (1,250% 2 290% lysis per mgikg, as compared with 77% f 15% for rt-PA, P < .003, and 36% f 7% for rscu-PA, P < .006) ( Table 3) . Linear regression analysis also showed a higher thrombolytic potency for rt-PA when administered as an infusion than as a bolus injection (160% ? 34% lysis per m a g and 77% ? 15%, respectively, P = .059>, but the difference between infusion and bolus administration for rscu-PA (43% 2 14% lysis per mgkg and 36% -c_ 7%, respectively) and for rt-PA-AFElscu-PA-e (1,100% 220% lysispermgkgand 1,250% 2 290%, respectively) were not statistically significant. However, the median effective doses, ED,,, at which 50% clot lysis is achieved, were 0.016 mgikg for rt-PA-AFE/scu-PA-e following bolus injection, as compared with 0.026 mgkg following continuous infusion, with corresponding values of 0.54 mgkg and 0.38 mgikg for rscu-PA and of 0.20 mgikg and 0.068 mgkg for rt-PA. Figure 2 illustrates the doseresponse curves normalized to equipotent fractional doses for rt-PA, rscu-PA, and rt-PA-AFE/scu-PA-e and their combinations. The relative thrombolytic potency of the combination of rt-PA and rscu-PA, determined as the slope of the normalized dose-response line, expressed in percent lysis per unit fractional dose, appeared to be higher when administered as a bolus than that of rt-PA or rscu-PA alone (220% f 27% lysis per unit fractional dose for the combination versus 100% lysis per unit fractional dose for the agents Tables 1 and 2. alone, P < .01 [ Table 41 ). The relative thrombolytic potency of the combinations of rt-PA or rscu-PA with rt-PA-AFE/scu-PA-e, administered as an infusion or as a bolus injection, was not significantly higher than that of each agent when administered alone ( Table 4 ). The thrombolytic potency of the combination of rt-PA with rscu-PA also was not synergistic when administered as an infusion. To confirm these surprising results, additional experiments were performed with infusion of rt-PA, rscu-PA, or rt-PA-AFE/scu-PA-e at their ED,, and combinations of two agents each at half of the respective ED,,. The results, summarized in Table 5 , indicate that lysis obtained with the combinations was not significantly higher than with the individual compounds, confirming the absence of a synergistic effect in the infusion experiments. Determination of t-PA-related or u-PA-related antigen in these experiments confirmed that the plasma clearance rate (Cl,) of rt-PA-AFE/scu-PA-e is more than 15-fold slower than that of rt-PA or of rscu-PA.
DISCUSSION
In an attempt to develop thrombolytic agents with improved thrombolytic properties, we recently developed a recombinant chimeric PA (rt-PA-AFE/scu-PA-e) that consists of the two kringle domains of t-PA and the serine protease domain of scu-PA." Although this chimera has much less fibrin-affinity than rt-PA, it has a markedly higher thrombolytic potency in vivo, due to an approximately 10-fold reduced clearance with maintained specific thrombolytic activity.I4 The present study was performed to evaluate the thrombolytic effect of intravenous bolus injections, as compared with intravenous infusions, of rt-PA-AFE/ scu-PA-e in hamsters with pulmonary embolism, and to evaluate a possible synergistic effect of the chimera with either rt-PA or rscu-PA. In this hamster pulmonary embolism model, human platelet-poor plasma clots are produced in vitro, and are thus not obtained under physiologic flow conditions. Our results confirm that the thrombolytic poFor personal use only. on August 30, 2017. by guest www.bloodjournal.org From tency of infusions of rt-PA-AFE/scu-PA-e is significantly higher than that of rt-PA or rscu-PA, and that its plasma clearance is more than 15-fold slower. In addition, the thrombolytic potency of bolus injection of rt-PA-AFE/scu-PA-e is also markedly higher than that of rt-PA or rscu-PA. rt-PA and rscu-PA, which have a short plasma half-life, appear to have a higher thrombolytic potency when administered as an infusion than when administered as a bolus injection, whereas rt-PA-AFElscu-PA-e was somewhat more potent after bolus injection than after infusion. Our results thus confirm that rt-PA-AFElscu-PA-e is an efficient thrombolytic agent, and suggest that the compound could be equally potent when administered as a bolus injection rather than as a continuous infusion. Thrombolysis is obtained in the absence of fibrinogen degradation or a,-antiplasmin consumption. The apparent increase of the fibrinogen levels may be the result of an acute phase reaction because these experiments were performed under nonsterile conditions. The lack of g-antiplasmin consumption indicates that systemic plasminogen activation in the hamster is only limited. Previous experiments in rabbits4 and dogs5 have shown a significant synergism between t-PA and scu-PA, whereas in humans results have been less encouraging.8 Our present results in hamsters with pulmonary embolism confirm that rt-PA and rscu-PA act synergistically, but only when administered as a bolus injection. On the other hand, no synergism was observed between combinations of rt-PA-AFE/scu-PA-e and rscu-PA, or of rt-PA-AFE/scu-PA-e and rt-PA either administered as an infusion or as a bolus injection. To evaluate a possible synergistic effect, dose-response curves were normalized (expressed as fractional dose) and slopes of the curves were obtained by linear regression analysis. Because these dose-response curves may not be strictly linear, a synergistic effect in a limited concentration range may have been missed. Therefore, we have performed additional experiments with continuous infusion of rt-PA, rscu-PA, or rt-PA-AFElscu-PA-e using ED,, doses and of their combinations at half of the respective ED,,. As shown in Table 5 , no significant synergism was obtained with any of the combinations, thus confirming our previous analysis. This absence of synergism between the chimera and rt-PA as compared with the presence of synergism between rscu-PA and rt-PA remains unexplained.
In conclusion, the thrombolytic profile of rt-PA-AFE/scu-PA-e may allow a significant reduction of the total amount of agent required for efficient thrombolysis and may allow its administration by bolus injection. It remains to be established to what extent these properties may be clinically useful.
